PAD infections arise from Peripheral Arterial Disease, a condition characterized by narrowed arteries that reduce blood flow to the limbs, particularly the legs. This reduced circulation can lead to painful ulcers, tissue necrosis, and severe infections. The lack of adequate blood flow in PAD makes it challenging for the body to fight off infections and heal wounds, increasing the risk of developing infections that can become critical if left untreated.

DeNovaMed’s Technological Approach: DeNovaMed is at the forefront of addressing PAD infections with our cutting-edge antibiotics. Our novel compounds, including DNM0547 and DNM0904, are tailored to target the resistant bacteria often involved in PAD infections. By focusing on disrupting bacterial lipid metabolism, our treatments offer a promising alternative to traditional antibiotics, which may be less effective due to the impaired circulation and prevalence of drug-resistant bacteria in PAD patients. Our innovative approach aims to improve patient outcomes, prevent tissue necrosis, and reduce the risk of severe complications such as amputation.